• Skip to main content
  • Skip to secondary menu
  • Skip to footer
Clinical Digital Resource Collaborative

Clinical Digital Resource Collaborative

Designed and developed in the North East and North Cumbria by local GPs

National Health Service
  • Home
  • About Us
  • The Team
  • Resources
    • Referral Forms
    • EMIS Resources
      • CDRC EMIS Access
      • Long Term Condition (LTC) Management
      • Impact and Investment Fund (IIF)
      • Medicine Management
        • Precision Monitoring
        • DMARDs and High Risk Drugs
        • Safe Prescribing of Opioids / Opiates
      • Specialties
        • Cancer Guide for EMIS
        • EMIS Cardiovascular Overview
          • Atrial Fibrillation Guide for EMIS
          • CDRC Precision CVD Prevention Template
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Guide for EMIS
          • Peripheral Arterial Disease EMIS Guide
        • Infection
          • Infections Guide for EMIS
          • Blood Borne Virus (BBV)
        • Neurology Guide for EMIS
        • Respiratory Overview
          • BeatAsthma+
    • SystmOne Resources
      • National Early Warning Score 2 (NEWS2) Guide for SystmOne
      • Getting Started
        • Getting Started – Access
        • Getting Started – How-To’s
      • SystmOne Administration
      • Contract Management
        • Batch Reporting
        • Impact and Investment Fund (IIF)
        • Vaccinations
      • Long Term Condition Management
        • Call/ Recall System
        • Recall Recovery System
        • Care Planning
      • Safeguarding System
        • Safeguarding Adults
        • Safeguarding At Risk of Harming Others
        • Safeguarding Family/Household Cause for Concern
        • Safeguarding Children
      • Medicine Management
        • Drugs Requiring Monitoring System
        • Safety & Reviews
        • Safe Prescribing of Opioids/ Opiates
        • Safe Prescribing of NSAIDS
        • Safe Prescribing of Lithium
        • Safe Prescribing of Valproate
        • Safe Prescribing of Corticosteroids / Steroids
      • Specialties
        • Blood Borne Virus (BBV) Test Alert for SystmOne
        • BeatAsthma+ Guide for SystmOne
        • Cancer Overview
          • Cancer
          • Suspected Cancer
        • Cardiovascular Overview
          • Cardiology Results
          • Hypertension & Blood Pressure
          • Atrial Fibrillation (AF)
          • Integrated CVD Prevention
          • Peripheral Arterial Disease (PAD)
        • ENT Infections
        • Geriatrics Overview
          • Care for Frail Patients
          • Comprehensive Geriatric Assessment
          • Co-ordinated Care
        • Haematology
        • Infection Overview
        • Learning Disabilities
        • Lifestyle
        • Lipids, Familial Hypercholesterolemia, PCSK9i & Inclisiran Overview
          • Performance Searches
          • Quality Improvement
          • Statin Safety
          • Lipids Protocols
          • Lipids Opt-In Resources
          • Lipids Details Template
          • Lipid Lowering Template
          • Lipid QoF Support
          • Screening for Familial Hypercholesterolaemia
          • Aetiology of Abnormal Lipids
          • Lipids Strategy
          • Lipids – Recommended Batch Searches
        • MSK Referral Management
        • Neurology
        • Obesity Resources
        • Ophthalmology
        • Palliative Care
        • Respiratory Overview
          • Asthma Resources
          • Respiratory Infections
        • Rheumatology Overview
          • Bone Health
      • Women’s Health Overview
        • Gynaecology Resource Overview
          • Cervical Screening
          • Contraception
          • Prolapse
      • Vaccination Overview
        • COVID-19 Resources- SystmOne
        • Influenza Vaccination
        • Meningitis B Vaccination
        • Meningitis ACWY Vaccination
        • Pneumococcal Vaccination
        • Shingles Vaccination
  • FAQs
  • News and Events
    • Demonstrations
    • Events
      • Recordings
    • Articles
    • Conference abstracts
  • Contact us
You are here: Home / Resources / SystmOne Resource Centre / SystmOne Specialties / Lipids, Familial Hypercholesterolemia, PCSK9i & Inclisiran Overview / Lipid Lowering Template

Lipid Lowering Template

The Lipid Lowering Template facilitates safe and effective management of lipid lowering treatments such as statins, ezetimibe and PCSK9i inhibitors 

How to Access

In the lower left hand corner use the search bar, type in ‘Lipid Lowering’ and select the following template:

Alternatively, press F12 and search for ‘Lipid Lowering’, this will return the aforementioned template.

Lipid Lowering Template Home Page

The Lipid Lowering page provides an overview of lipid lowering treatment.

Lipid Lowering Atonxastatin 
Fluvastatin Pravastatin Rosuvastatin Simvastatin Ezetimibe PCSKgi Statin Potency 
Lipid Lowering 
NICE Lipid Pathway OU Vpid Pathway! 
PRIMARY PREVENTION likely to be recommended 
A O Details 
Q QRISK 
03 
2 Calculator 
Statin Cates Plot 
0 
PIL Statin Patient Decision Aid 
Calculate Target Non HDL-C 
Target Non HDL-C 
Statin offered 
Lipid Lowering Declined 
Lipid Lowering Not Indicated 
Default Rx 
Primary prevention - atorvastatin 20mg 
Secondary prevention - atorvastatin 80mg 
Atorvastatin 
Fluvastatin 
Pravastatin 
Rosuvastatin 
Simvastatin 
Ezetimibe 
PCSKgi 
Lipid Lowering Checklist 
4 Feb 2021 
Feb 2021 
3 2021 
3 2021 
3 2021 
3 2021 
04 Feb 2021 
QRlSK2 cardiovascular disease 10 year risk sc 
serum HDL cholesterol level (44P5J (SNOMECI 
serum triglyceride levels (SNOMEO: 10 
Serum non high density lipoprotein cholesterol 
serum cholesterol level [XE2eO) (SNOMEO: 10 
serum LDL cholesterol level (44P6J (SNOMED 
23 
1 3 mmol/L 
113 mmol/L 
3Æ mmol/L 
5M mmol/L 
31 mmol/L 
Target serum non high density lipoprotein cholest.„ 23 mmol/l 
Atorvastatin 20mg tablets 
26 Mar take 
Lipid target NOT achieved 
lg sep 2017 statin declined oxalil) (SNOMED: 1343g6000) 
Lipid Lowering Checklist 
2 
04 Feb 2021 14:11 
Lipid Resuts Table 
A Medication Timeline 
Lipid Resuts wth Lipid Rx 
Expand 
Entered by 
Finished by 
WILKINSON, Susan (Sister) (Nurse Access Role) 
WILKINSON, Susan (Sister) (Nurse Access Role) [04 Feb 2021 
Lipid Narrative 
Lipid Lowering Treatment 
Told to avoid drink grapefruit 
juice 
Asked to report muscle pain, 
tenderness or weakness 
Asked to report 
breathlessness, dry cough 
Atorvastatin 
Yes 
Yes 
Yes
Column 1 Column 2 Column 3 
 As summary of the indications for lipid lowering  The button will open a screen showing more details e.g.  y OCS Lipids Risk - Conditions 
16 Jan 2018 QRISK2 cardiovascular disease 10 year risk score (SNOMED: 71 8087004) 
NO clear record of CHD 
NO clear record of code for CKD 
No record of diabetes 
NO clear record of code for strokeyTlA 
Close 
log7%  
Link to QRISK2 calculator Most recently recorded QRISK2 score  
Link to website with statin Cates plots – this webpage will be opened with the patient’s most recent QRISK2 score. Link to the NICE Statin Patient Decision Aid Most recent lipid results Link to TPP lipid table/graph 
Button to calculate a target non-HDL cholesterol, based on achieving a 40% reduction in non-HDL choletesterol Box to manually enter target non-HDL cholesterol, if needed, e.g. if the most recent non-HDL cholesterol is ‘on treatment’. Most recent cholesterol (and triglyceride if present) targets.  
 Current repeat lipid lowering Warnings and alerts, including: Consider starting lipid lowering Poor concordance/compliance Consider setting lipid target Target not achieved Consider statin intensification Link to the Medication Timeline which shows a schematic of all previous medication Link to Lipids Results and Lipid Rx which shows a list of lipid lowering medication and lipid results so response to treatment and concordance can be assessed eg.  15 Jan 2018 
2018 
15 Jan 2018 
2018 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
serum HDL cholesterol level (44P5J (SNOMED: 1 005681 0000001 07) 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
10061 glo 
27 mmol/L 
4 mmol/L 
1 2 mmol/L 
51 mmol/L 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
2g May 2018 Serum non high density lipoprotein cholesterol level [XabE1) (SNOMEC) 
2g May 2018 serum HDL cholesterol level (44P5J (SNOMED: 1005681 0000001 07) 
May 2018 serum cholesterol level (SNOMED: 10056710000001 05) 
2g May 2018 serum LDL cholesterol level (4496) (SNOMED: 10221 el 0000001 00) 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
05 Jun 201g 
serum HDL cholesterol level (4495) (SNOMED: 1 005681 0000001 07) 
05 dun 201g 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
05 Jun 201g 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
05 dun 201g 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
Atorvastatin 20mg tablets 
take one daily 
06 Feb 2018 
06 Mar 2018 
26 Mar 2018 
24 Apr 2018 
21 May 2018 
10061g10 1 
1 2 mmol/L 
2Æ mmol/L 
1M mmol/L 
2018 
13 dui 2018 
15 Aug 2018 
17 sep 2018 
16 Oct 2018 
13 Nov 2018 
06 2018 
08 201g 
05 Feb 201'? 
05 Mar 201g 
26 Mar 
24 Apr 201 g 
23 May 201'? 
14 mmol/L 
10061g10 2 mmoI/L 
1 3 mmol/L 
34 mmol/L 
18 dun   
Tickbox for statin offered Buttons to record that lipid lowering if declined or not indicated – the protocol which runs from this button will check if all lipid lowering therapy is declined or not indicated or just statins. Most recent codes indicating that lipid lowering is not appropriate e.g. declined, not indicated, not tolerated.   A warning will be displayed if the patient has a S1 ADR to statins recorded but not a Snomed code A button to show all previous lipid lowering exception codes and S1 lipid lowering ADR information. e.g. OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
Drug Allergies 
22 2013 SIMVASTATIN 
Notes 
Entered 
Muscle aches at 80mg 
22 Aug 201 3 og:53 by FORBES, Gareth (Dr) (General Medical Practitioner)  OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
02 Mar 2011 
statin not indicated (SNOMED: 1 343g1 005) 
Drug Allergies 
b 26 Novigga 
Entered 
28 Apr2015 
Notes 
Entered 
FLUCLOXACILLIN 
26 Nov 1 get by ASTLEY, David (Dr) 
ATORVASTATIN 
generally unwell, mood changes 
28 Apr 201 5 og:1 6 by GREENFIELD, Claire (Dr) (Clinical Practitioner Access Role)  
Links to tabs for individual lipid lowering medication Button to run lipid lowering checklist – this protocol runs a series of checks looking at drug indication, dosing, lipid targets, drug interactions and provides a checklist for key information about the prescribing with information for the patient.  Lipid Narrative 
Lipid Lowering Treatment 
Atorvastatin 
Fluvastatin 
Pravastatin 
ROsuvastatin 
Simvastatin 
Ezetimibe 
Praluent 
Repatha 
Asked to report muscle pain, tenderness or weakness 
O Yes 
O No 
O Not known 
Asked to report breathlessness, dry cough 
O Yes 
O No 
O Not known 
Pregnancy, contraception, breastfeeding discussed 
O Yes 
O No 
Not known  The latest contents of the lipid lowering checklist  

Pages for for Individual Drugs

Pages for the individual drugs show key prescribing and safety information.  Key information (such as renal function) is shown in the middle panel, along with warnings about potential safety issues and interactions. 

There are buttons for: 

  • Creating new repeat of atorvastatin 20mg 
  • Creating new repeat of a different dose of atorvastatin 
  • Creating statin PIL 
  • Creating a scheduled task for checking lipids and LFTs in 3m (for routine monitoring after initiation) 
  • Running the lipid lowering checklist 
Lipid Lowering Atonxastatin 
Atorvastatin 
Moderate Potency 10mg 
High Potency 20, 40, 80mg 
Renal 
Avoid doses >20mg if eGFR 
Caution 
Fluvastatin 
-30 
Pravastatin 
Rosuvastatin Simvastatin Ezetimibe PCSKgi Statin Potency 
Has record of a HYPERLIPIDAEMIA 
PRIMARY PREVENTION likely to be recommended 
23 Mar 200g 
UBS cardiovascular disease risk -20% up to 30% ov next 10 
Atorvastatin 20mg tablets 04 Jun taken 28 t 
NO clear record of lipid lowering ADRs or exceptions 
Drug Allergies 
GFR calculated abbreviated MORD 
Serum alanine aminotransferase level 
AST serum level 
Serum creatine kinase level 
Alcohol intake 
Details 
Lipid ResutsyFx 
Expand 
Expand 
Amiodarone, ditliazem, dronedarone, sacubitril, verapamil 
Bezaflbrate, ciproflbrate, ezetimibe, fenoflbrate 
Grapefruitjuice 
Leflunomide, teriflunamide 
Fluconazole, miconazole, itraconazole, posaconazole 
Erythromycin 
Avoid'Contraindicated 
Clarithromycin 
Gemflbrozil 
Ciclosporin (and do not use doses above 10mg) 
Doses above 20mg with certain HIV drugs 
New repeat of Atorvastatin 20mg tablets 
New Repeat of other dose 
PIL Statin 
Scheduled Task - lipids and LFTs in 3m 
Lipid Lowering Checklist 
87 mLJmin/1 73m 
15 iu/L 
lg iu/L 
107 iu/L 
28 unitsmeek 
03 Mar 2021 
03 Mar 2021 
23 Mar 200g 
03 Apr 2007 
04 Nov 2020 
! CAUTION - ON DILTIAZEM - RISK OF INTERACTION 
DCS Lipid Lowering - Checklist view has no data for patient

Statin Potency Page 

Shows statin potencies 

Statin Potency 
ow potency- Fluvastatin 20 40; Pravastatin 10 20 40; Simvastatin 10 
Moderate Potency - Fluvastatin 80; Simvastatin 20 j 40; Atonxastatin 10; Rosuvastatin 5mg 
High Potency- Simvastatin 80*; Atonxastatin 20 j 40 j 80; Rosuvastatin 10 20 j 40 
* Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatirL The 80 mg 
dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular 
complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh 
the potential risk. 
NICE Grouping

Footer

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter
  • Terms of Reference
  • Ethics & Governance
  • Privacy policy
  • Terms of use
  • Join CDRC Precision

Copyright © 2023 Clinical Digital Resource Collaborative